Levetiracetam
Brand: Keppra (US/EU) / Levipil (IN) / Levepsy (BD)
Anticonvulsant
SV2A modulator
Pharmacokinetics
| Half-life | 7 hours |
| Tmax | 1 h |
| Bioavailability | 100 % (approx) |
| Protein Binding | 10 % |
| Volume of Distribution | 0.5 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Renally cleared; minimal hepatic metabolism; very few interactions; psychiatric irritability side effect sometimes. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Somnolence, fatigue, behavioral irritability, mood changes
Contraindications:
Known hypersensitivity
Precautions:
Monitor behavior/mood; adjust dose in renal impairment